At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Phase 2a Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Orally Administered Investigational Capsid Inhibitor Monotherapy in HIV-1 Infected Treatment-Naïve Adults
In Brief
A Phase 2 clinical trial evaluating VH4004280, VH4011499, and 3 other interventions for HIV Infections. Completed, enrolled 44 participants across 20 sites in 9 countries.
Detailed Summary
The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-Naïve (TN) participants.
Study Details
Timeline
Interventions
VH4004280 was administered as tablets orally at Day 1.
VH4011499 was administered as tablets orally at Day 1 and Day 6.
VH4004280 Matching Placebo was administered as tablets orally at Day 1.
VH4011499 Matching Placebo was administered as tablets orally at Day 1 and Day 6.
Antiretroviral therapy was administered as available and as per investigator's recommendation.